《盈警響號》中智藥業(03737.HK)料去年利潤跌至9,000萬人幣
中智藥業(03737.HK)公布,預期截至去年12月底止年度將錄得利潤約9,000萬元人民幣(下同)(未經非上市理財產品公平值調整),相對於2020年同期純利為1.39億元。
公司解釋,主要由於全球原材料(包括金屬及中藥材)價格上漲導致整體生產成本增加;宣傳公司產品及品牌的廣告開支增加導致銷售及分銷開支增加;及2021年上半年因擴大營運增加員工人數導致薪金開支增加。
此外,集團正在對集團從一家銀行購買的本金額為3,700萬元的若干非上市理財產品的潛在公平值調整進行落實,有關理財產品因中國物業開發商發行的若干債券存在不確定性而逾期贖回。集團正積極尋求法律意見並將對有關發行人採取一切必要的法律措施,盡可能收回任何投資損失。而上述非上市理財產品的任何潛在公平值調整可能會進一步減少集團截至去年度的純利。但公司指,非上市理財產品的逾期贖回將不會對公司營運造成重大不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.